The role of tailored intraoperative neurophysiological monitoring in glioma surgery: a single institute experience

Pan, Szu-Yen; Chen, Junpeng; Cheng, Wen-Yu; Lee, Hsu‐Tung; Shen, Chiung‐Chyi

doi:10.1007/s11060-019-03347-0

Cited by 13 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, patients can benefit from technological advances and refinement of surgical tools, which help maximize the extent of tumor resection while minimizing morbidities. For instance, multimodal imaging integrated with preoperative MRI, diffusion tractography imaging [ 17 ], functional MRI, intraoperative MRI [ 18 ], neurophysiological monitoring [ 19 ], intraoperative US [ 20 ], and 5-aminolevulinic acid (5-ALA)-based fluorescence imaging can help neurosurgeons identify precise tumor margins and avoid damage to eloquent areas and neural fibers [ 21 ].…”

Section: Current Treatment Status Of Gbmmentioning

confidence: 99%

Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

et al. 2022

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, and it is associated with poor prognosis. Its characteristics of being highly invasive and undergoing heterogeneous genetic mutation, as well as the presence of the blood–brain barrier (BBB), have reduced the efficacy of GBM treatment. The emergence of a novel therapeutic method, namely, sonodynamic therapy (SDT), provides a promising strategy for eradicating tumors via activated sonosensitizers coupled with low-intensity ultrasound. SDT can provide tumor killing effects for deep-seated tumors, such as brain tumors. However, conventional sonosensitizers cannot effectively reach the tumor region and kill additional tumor cells, especially brain tumor cells. Efforts should be made to develop a method to help therapeutic agents pass through the BBB and accumulate in brain tumors. With the development of novel multifunctional nanosensitizers and newly emerging combination strategies, the killing ability and selectivity of SDT have greatly improved and are accompanied with fewer side effects. In this review, we systematically summarize the findings of previous studies on SDT for GBM, with a focus on recent developments and promising directions for future research.

show abstract

Section: Current Treatment Status Of Gbmmentioning

confidence: 99%

Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Currently, patients benefit from the advancement of technologies and refinement of surgical tools that can help maximize the extent of tumor resection with minimized morbidities. Such technologies include multimodal imaging integrated with preoperative magnetic resonance imaging (MRI), diffusion tractography imaging (Shukla et al, 2017), functional MRI and intraoperative MRI (Napolitano et al, 2014), neurophysiological monitoring (Pan et al, 2020), intraoperative ultrasound (US) (Prada et al, 2016), and 5-aminolevulinic acid (5-ALA)-based fluorescence imaging (Della Puppa et al, 2019), which can help neurosurgeons achieve a delicate balance between the maximum resection of tumor tissue and the minimum damage to the surrounding normal bundle.…”

Section: Surgerymentioning

confidence: 99%

Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies

Liu

Wang

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) represents the most common and fatal form of primary invasive brain tumors as it affects a great number of patients each year and has a median overall survival of approximately 14.6 months after diagnosis. Despite intensive treatment, almost all patients with GBM experience recurrence, and their 5‐year survival rate is approximately 5%. At present, the main clinical treatment strategy includes surgical resection, radiotherapy, and chemotherapy. However, tumor heterogeneity, blood–brain barrier, glioma stem cells, and DNA damage repair mechanisms hinder efficient GBM treatment. The emergence of nanometer‐scale diagnostic and therapeutic approaches in cancer medicine due to the establishment of nanotechnology provides novel and promising tools that will allow us to overcome these difficulties. This review summarizes the application and recent progress in nanotechnology‐based monotherapies (e.g., chemotherapy) and combination cancer treatment strategies (chemotherapy‐based combined cancer therapy) for GBM and describes the synergistic enhancement between these combination therapies as well as the current standard therapy for brain cancer and its deficiencies. These combination therapies that can reduce individual drug‐related toxicities and significantly enhance therapeutic efficiency have recently undergone rapid development. The mechanisms underlying these different nanotechnology‐based therapies as well as the application of nanotechnology in GBM (e.g., in photodynamic therapy and chemodynamic therapy) have been systematically summarized here in an attempt to review recent developments and to identify promising directions for future research. This review provides novel and clinically significant insights and directions for the treatment of GBM, which is of great clinical importance. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

show abstract

“…While prior studies have not identified a patient survival advantage with the use of neuromonitoring, monitoring for functional preservation has remained a primary objective with the use of IONM [104]. Despite previous criticisms of false-negative motor evoked potential (MEP) monitoring affecting IONM reliability, previous studies have shown reliability in MEP monitoring, with few to no false-negative results [105,106].…”

Section: Intraoperative Neurophysiologic Monitoring (Ionm)mentioning

confidence: 99%

The Neurosurgeon’s Armamentarium for Gliomas: An Update on Intraoperative Technologies to Improve Extent of Resection

Schüpper

Yong

Hadjipanayis

2021

JCM

View full text Add to dashboard Cite

Maximal safe resection is the standard of care in the neurosurgical treatment of high-grade gliomas. To aid surgeons in the operating room, adjuvant techniques and technologies centered around improving intraoperative visualization of tumor tissue have been developed. In this review, we will discuss the most advanced technologies, specifically fluorescence-guided surgery, intraoperative imaging, neuromonitoring modalities, and microscopic imaging techniques. The goal of these technologies is to improve detection of tumor tissue beyond what conventional microsurgery has permitted. We describe the various advances, the current state of the literature that have tested the utility of the different adjuvants in clinical practice, and future directions for improving intraoperative technologies.

show abstract

The role of tailored intraoperative neurophysiological monitoring in glioma surgery: a single institute experience

Cited by 13 publications

References 34 publications

Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies

The Neurosurgeon’s Armamentarium for Gliomas: An Update on Intraoperative Technologies to Improve Extent of Resection

Contact Info

Product

Resources

About